ENLIVEX THERAPEUTICS LTD ENLV 深 沪
等待开盘 12-20 09:30:00 美东时间
0.82
-0.012
-1.39%
华盛通- 最 高1.245
- 今 开0.83
- 成交量 57.10万股
- 最 低 0.7936
- 昨 收 0.8316
- 总市值 1506.62万
- 52周最高 2.10
- 市盈率 静 --
- 换手率 3.11%
- 52周最低 0.7936
- 委 比 20.00%
- 总股本 1837.34万
- 历史最高 44.90
- 量 比 0.62
- 振 幅 54.28%
- 历史最低 0.7936
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dow Jumps 300 Points; Waldencast Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
11-25 01:08
D. Boral Capital Downgrades Enlivex Therapeutics to Hold
D. Boral Capital analyst Jason Kolbert downgrades Enlivex Therapeutics (NASDAQ:ENLV) from Buy to Hold.
11-24 23:41
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more ...
11-24 22:47
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
Enlivex Therapeutics will present data on its Allocetra™ therapy for knee osteoarthritis at the EULAR Congress in Barcelona. The presentation will highlight promising results from ongoing Phase I/II trials, including pain reduction and improved joint function, with Phase II data expected by August 2025.
06-10 12:30
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $6 price target.
2024-09-09 18:22
EF Hutton Initiates Coverage On Enlivex Therapeutics with Buy Rating, Announces Price Target of $13
EF Hutton analyst Jason Kolbert initiates coverage on Enlivex Therapeutics (NASDAQ:ENLV) with a Buy rating and announces Price Target of $13.
2024-08-27 20:07
